[go: up one dir, main page]

MX2022000960A - Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr. - Google Patents

Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.

Info

Publication number
MX2022000960A
MX2022000960A MX2022000960A MX2022000960A MX2022000960A MX 2022000960 A MX2022000960 A MX 2022000960A MX 2022000960 A MX2022000960 A MX 2022000960A MX 2022000960 A MX2022000960 A MX 2022000960A MX 2022000960 A MX2022000960 A MX 2022000960A
Authority
MX
Mexico
Prior art keywords
tapinarof
skin
egfr inhibitor
ichthyosis
psoriasis
Prior art date
Application number
MX2022000960A
Other languages
English (en)
Inventor
Ofer Toledano
Karine Neimann
Ori Nov
Moshe Arkin
Marcel Zighelboim
Djerbi Hila Hakak
Original Assignee
Sol Gel Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sol Gel Tech Ltd filed Critical Sol Gel Tech Ltd
Publication of MX2022000960A publication Critical patent/MX2022000960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

Se describen composiciones tópicas y métodos de tratamiento de un trastorno de la piel o las mucosas seleccionado de psoriasis palmoplantar, queratodermia palmoplantar hereditaria, queratodermia palmoplantar adquirida, hidradenitis supurativa, dermatitis, ictiosis vulgar, ictiosis hereditaria, ictiosis adquirida, queratosis actínica, un trastorno de queratinización de la piel, un trastorno de queratinización de la mucosa, síndrome de Gorlin, psoriasis ungueal, psoriasis flexural/inversa, cáncer de piel no melanoma y lesiones precancerosas de la piel, mucosas y uñas, mediante la administración tópica a un sujeto una o dos veces por día de una composición que comprende como agente/s activo/s cantidades terapéuticamente eficaces de tapinarof, al menos un inhibidor de EGFR y combinaciones de tapinarof-inhibidor/es de EGFR.
MX2022000960A 2019-07-24 2020-07-23 Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr. MX2022000960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877966P 2019-07-24 2019-07-24
US202063005353P 2020-04-05 2020-04-05
PCT/IL2020/050817 WO2021014447A1 (en) 2019-07-24 2020-07-23 Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions

Publications (1)

Publication Number Publication Date
MX2022000960A true MX2022000960A (es) 2022-03-22

Family

ID=74193684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000960A MX2022000960A (es) 2019-07-24 2020-07-23 Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.

Country Status (8)

Country Link
US (1) US20220142944A1 (es)
EP (1) EP4003299A4 (es)
JP (1) JP2022541605A (es)
KR (1) KR20220041125A (es)
CN (1) CN114206315A (es)
CA (1) CA3147740A1 (es)
MX (1) MX2022000960A (es)
WO (1) WO2021014447A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160126A1 (en) * 2019-11-06 2021-05-14 Sol-Gel Technologies Ltd. Method of treating palmoplantar keratoderma
CN115803007A (zh) * 2020-04-07 2023-03-14 C.T.R.S.实验室公司 厄洛替尼在治疗儿童角化病中的局部应用
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
CN118490636B (zh) * 2023-02-16 2025-07-18 济川(上海)医学科技有限公司 本维莫德纳米乳组合物，包含其的药物制剂，及其制备方法和应用
TW202519195A (zh) * 2023-11-02 2025-05-16 大陸商上海澤德曼醫藥科技有限公司 苯酚衍生物的溶液型藥物組合物及其製劑和用途
WO2025147179A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393297C (en) * 1999-12-06 2010-10-05 Welichem Biotech Inc. Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
EP1370294A2 (en) * 2001-02-27 2003-12-17 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
WO2009091889A1 (en) * 2008-01-18 2009-07-23 Georgetown University Treatment of skin disorders with egfr inhibitors
CN102657602B (zh) * 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9687465B2 (en) * 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
DK3297605T3 (da) * 2015-05-21 2022-06-07 Dermavant Sciences GmbH Topiske, farmaceutiske sammesætninger
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
BR112021006407A8 (pt) * 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
EP3902524A4 (en) * 2018-12-25 2022-09-14 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions

Also Published As

Publication number Publication date
WO2021014447A1 (en) 2021-01-28
JP2022541605A (ja) 2022-09-26
KR20220041125A (ko) 2022-03-31
EP4003299A1 (en) 2022-06-01
EP4003299A4 (en) 2023-08-23
CA3147740A1 (en) 2021-01-28
CN114206315A (zh) 2022-03-18
US20220142944A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
MX2022000960A (es) Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.
Van De Kerkhof et al. Brittle nail syndrome: a pathogenesis-based approach with a proposed grading system
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
CO6460708A2 (es) Composiciones borínicas
BR112015005339A8 (pt) uso de óleo de semente de fruta milagrosa como um ingrediente ativo
BRPI0910874A8 (pt) composições e métodos para cuidado da pele
BRPI0700861A (pt) poliuretano, composição cosmética ou farmacêutica e processo de tratamento cosmético
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
CU24449B1 (es) Agentes activos que tienen un doble enlace carbono-carbono, útiles en una composición para tratar el cabello
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
BRPI1006826A2 (pt) Composições para melhorar o crescimento de unhas
AR045504A1 (es) Composicion de ester ramificado
TW200744661A (en) Topical cosmetic formulations for regulating and improving the moisture content of the skin
BRPI0700914A (pt) composição cosmética para aplicação tópica, usos da composição e processo de tratamento das matérias queratìnicas
BR112013001057A2 (pt) composição para o tratamento de lesões superficiais
EP4552650A3 (en) Methods and compositions for treatment of skin
MX394384B (es) Formulacion para analogos anticolinergicos blandos.
MX2024005303A (es) Formulaciones biotensioactivas para su uso en el cuidado de la piel y el tratamiento de heridas.
MX2023005658A (es) Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.
BRPI0715361B8 (pt) uso de polietileno glicol em inflamação relacionada com doenças ou distúrbios tópicos e cicatrização de ferimento
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
FR2947727B1 (fr) Composition cosmetique a usage topique, trousse en comportant, procede cosmetique modulable en fonction du vieillissement de la peau la mettant en oeuvre
BRPI0517826A (pt) uso de extratos vegetais para prevenir e/ou reduzir os sinais de desconforto subjetivo e/ou irritação na aplicação tópica de produtos cosméticos
WO2008051557A3 (en) Methods and compositions for treatment of skin conditions